6:01 PM · 13 April 2021

Moderna stock rose 7% after FDA halt use of JNJ vaccine

The news that the Johnson & Johnson (JNJ.US) vaccine would be paused appeared to be beneficial for Moderna (MRNA.US) which shares gained more than 7% following FDA announcement. The drugmaker has also issued a statement saying that data indicates its COVID-19 vaccine is not associated with cerebral venous sinus thrombosis ("CVST") or other thrombotic events. Moderna announced that assessment was made based on safety data through March 22 of more than 64.5M doses administered worldwide.

Moderna (MRNA.US) stock launched today's session with a bullish price gap and is currently testing the upper limit of the descending channel which coincides with 50 SMA (green line). Source: xStation5

7 July 2026, 6:02 PM

Uranium stocks after the selloff 📉 Uranium Energy Corp. tumbles 50% from its highs

7 July 2026, 5:16 PM

Nasdaq selloff 🚩 DeepSeek and Samsung earnings reaction sink semiconductor stocks

7 July 2026, 3:32 PM

SpaceX crashes 6% despite a wave of bullish Wall Street initiations 📉

7 July 2026, 2:55 PM

US Open: US100 loses 1% as semiconductors retreat 📉 BigTech stocks and DJIA gain

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits